SAB Biotherapeutics (NASDAQ:SABS) Posts Earnings Results, Hits Estimates

SAB Biotherapeutics (NASDAQ:SABS) announced its quarterly earnings results on Thursday. The company reported ($0.28) earnings per share for the quarter, meeting the consensus estimate of ($0.28), FiscalAI reports.

Here are the key takeaways from SAB Biotherapeutics’ conference call:

• SAFEGUARD enrollment is accelerating, with more than 60 sites actively recruiting and increased screening and randomization. Management remains on track to complete enrollment in Q4 2026, with top-line data expected in the second half of 2027.
• Breakthrough T1D awarded a grant supporting the PRISE-hATG Phase III study, which is expected to begin enrollment in the second half of 2026 across seven sites. If successful, the study could support a future SAB-142 label expansion for patients treated up to two years after diagnosis, with top-line data expected in Q1 2029.
• SAB Bio ended the quarter with $208 million in cash, cash equivalents, and investments, providing an operating runway through 2028. However, higher clinical-development and headcount costs drove R&D expense to $16.2 million and the net loss to $22.5 million, versus $10.1 million a year earlier.
• Management views the recent FDA approval of Tzield in recently diagnosed Stage 3 Type 1 diabetes as validation that C-peptide can support an accelerated-approval pathway. SAB Bio also highlighted SAB-142’s potential competitive advantages, including two-day dosing and low to no immunogenicity that may enable redosing.

SAB Biotherapeutics Price Performance

SAB Biotherapeutics stock traded up $0.08 during midday trading on Thursday, hitting $3.85. 279,785 shares of the company’s stock were exchanged, compared to its average volume of 683,940. The company has a market cap of $294.39 million, a P/E ratio of -1.82 and a beta of 0.53. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.45 and a current ratio of 11.45. The stock has a 50-day moving average price of $3.68 and a two-hundred day moving average price of $3.83. SAB Biotherapeutics has a 52-week low of $1.85 and a 52-week high of $5.15.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on SABS shares. Barclays began coverage on SAB Biotherapeutics in a report on Wednesday, June 24th. They set an “overweight” rating and a $13.00 price objective on the stock. Zacks Research upgraded SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, May 11th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of SAB Biotherapeutics in a report on Monday, June 15th. Leerink Partners raised their price objective on shares of SAB Biotherapeutics from $7.00 to $12.00 and gave the company an “outperform” rating in a research report on Monday, June 15th. Finally, Wall Street Zen cut shares of SAB Biotherapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $12.00.

Institutional Trading of SAB Biotherapeutics

A number of large investors have recently modified their holdings of SABS. ADAR1 Capital Management LLC increased its position in shares of SAB Biotherapeutics by 75.6% in the fourth quarter. ADAR1 Capital Management LLC now owns 26,344 shares of the company’s stock worth $99,000 after purchasing an additional 11,344 shares during the last quarter. ExodusPoint Capital Management LP bought a new stake in SAB Biotherapeutics during the fourth quarter valued at approximately $322,000. OMERS ADMINISTRATION Corp purchased a new position in SAB Biotherapeutics in the 4th quarter worth approximately $157,000. Verition Fund Management LLC purchased a new position in SAB Biotherapeutics in the 4th quarter worth approximately $100,000. Finally, Marshall Wace LLP bought a new position in shares of SAB Biotherapeutics in the 4th quarter worth $884,000. Institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.